CD274 and esophageal adenocarcinoma: In conclusion, nivolumab plus chemotherapy is unlikely to be considered cost-effective compared with chemotherapy alone in the first-line therapy for advanced or metastatic PD-L1 CPS ≥5 GC/GEJC/esophageal adenocarcinoma from the perspective of the Chinese healthcare system.